Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Efficacy and Safety of Immune Checkpoint Inhibitors for Patients With Prostate Cancer: A Systematic Review and Meta-Analysis Publisher Pubmed



Noori M1, 2 ; Azizi S1 ; Mahjoubfar A1 ; Abbasi Varaki F1 ; Fayyaz F3, 4, 5 ; Mousavian AH2, 6 ; Bashash D7 ; Kardoust Parizi M8, 9 ; Kasaeian A2, 6, 10
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Hematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  5. 5. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  6. 6. Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  8. 8. Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  9. 9. Department of Urology, Medical University of Vienna, Vienna, Austria
  10. 10. Clinical Research Development Unit, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Frontiers in Immunology Published:2023


Abstract

Immunotherapy has revolutionized the treatment paradigm of many cancers, however, its effectiveness in prostate cancer patients is still under question. In the present systematic review and meta-analysis, we sought for assessing the efficacy and safety of Immune checkpoint inhibitors (ICIs) in patients with prostate cancer. PubMed, Scopus, Web of Science, and EMBASE databases were searched on Aguste 19, 2022. Thirty five studies met the eligibility criteria. The median overall survival (mOS) of all treatments was 14.1 months, with the longest and shortest mOS was seen among patients who received anti-CTLA-4 monotherapy and anti-PD-1/PD-L1+anti-CTLA-4 regimen at 24.9 and 9.2 months, respectively. Noteworthy, all types of adverse events had the lowest incidence in the anti-PD-1/PD-L1 monotherapy group. Considering the ICI monotherapy regimens, we found that fatigue, diarrhea, and infusion reaction had the highest incidence rates. Future studies evaluating the efficacy and safety of novel combination therapies with ICIs are warranted. Copyright © 2023 Noori, Azizi, Mahjoubfar, Abbasi Varaki, Fayyaz, Mousavian, Bashash, Kardoust Parizi and Kasaeian.
Other Related Docs
12. Chemotherapy: A Double-Edged Sword in Cancer Treatment, Cancer Immunology# Immunotherapy (2022)
22. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
24. A Systematic Review of the Effect of Lavender on Cancer Complications, Complementary Therapies in Medicine (2022)
36. Breast Cancer: Biology, Biomarkers, and Treatments, International Immunopharmacology (2020)